风湿免疫疾病是一种病因尚未完全明了的疾病，临床表现多样。临床治疗主要使用非甾体抗炎药、糖皮质激素和以改善病情为主合成类抗风湿药物。随着近年对发病机制的深入研究，出现了一系列作用于靶向细胞因子或细胞表面受体的以改善病情为主的生物药物。药物种类也从小分子发展到单克隆抗体再到融合蛋白等，从而加速了抗风湿免疫药物更加有效安全地被用于临床治疗。分析了非甾体抗炎药、糖皮质激素类药物、以改善病情为主的抗风湿药的临床使用情况，为发现更加低毒有效地治疗风湿免疫疾病药物提供了途径。

Rheumatoid immune disease is a chronic systemic inflammatory disease with unknown etiology. It is an autoimmune disease mainly characterized with pain symptoms. In clinical, nonsteroidal anti-inflammatory drugs, glucocorticoids, and synthetic disease-modifying anti-rheumatic drugs are used alone or in combination to improve inflammation and reduce pain. However, with the in-depth study of the pathogenesis and the rapid development of molecular biology in recent years, a series of biological disease- modifying anti-rheumatic drugs targeting cytokines or cell surface receptors have been developed. At the same time, the types of drugs have also developed from low-molecule-weight synthetic disease-modifying anti-rheumatic drugs to monoclonal antibodies and fusion proteins, thereby accelerating the use of anti-rheumatic immune drugs in clinical treatment more effectively and safely. This paper analyzes the clinical use of nonsteroidal anti-inflammatory drugs, glucocorticoids, and anti-rheumatic drugs, which are mainly used to improve the condition of the patients, so as to provide a way to find more effective and less toxic drugs for the treatment of rheumatic immune diseases.

R977